106 related articles for article (PubMed ID: 3463242)
1. CA 15.3: early results of a new breast cancer marker.
Colomer R; Sole LA; Navarro M; Encabo G; Ruibal A; Salvador L
Anticancer Res; 1986; 6(4):683-4. PubMed ID: 3463242
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of a tumor-associated antigen CA 15-3 in the sera of patients with breast cancer].
Ogawa T; Izuo M; Morita H; Ishida T; Iino Y; Hoshino K; Yokoe T; Suzuki H; Murata S; Matsuzaki S
Gan No Rinsho; 1986 Jan; 32(1):27-32. PubMed ID: 3456454
[TBL] [Abstract][Full Text] [Related]
3. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker.
Bray KR; Koda JE; Gaur PK
Cancer Res; 1987 Nov; 47(22):5853-60. PubMed ID: 2444335
[TBL] [Abstract][Full Text] [Related]
4. CA15-3 serum levels in breast cancer and other malignancies--correlation with clinical course.
Barak V; Carlin D; Sulkes A; Treves A; Biran S
Isr J Med Sci; 1988; 24(9-10):623-7. PubMed ID: 3204010
[TBL] [Abstract][Full Text] [Related]
5. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].
Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634
[TBL] [Abstract][Full Text] [Related]
6. [Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA].
Komuro K; Watanabe K; Ishida T; Sakurai M; Amano R; Hagiwara H; Hara Y; Hanzawa T; Itsubo K
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3145-9. PubMed ID: 3465273
[TBL] [Abstract][Full Text] [Related]
7. Experience with CA 15.3 as a tumor marker in breast cancer.
Barros AC; Fry W; Nazario AC; Santos MO; Sato MK
Eur J Surg Oncol; 1994 Apr; 20(2):130-3. PubMed ID: 8181577
[TBL] [Abstract][Full Text] [Related]
8. Comparison of tumour markers TAG 12 with CA 15-3 and MCA in breast cancer diagnosis.
Eskelinen M; Hippelainen M; Salmela E; Paajanen H; Carlsson L; Jonsson P; Alhava E
Anticancer Res; 1992; 12(1):39-42. PubMed ID: 1567179
[TBL] [Abstract][Full Text] [Related]
9. [Estimates of circulating breast cancer-associated antigen CA 15-3 as a monitoring marker in patients with breast cancer].
Yoshimoto M; Akiyama F; Watanabe S; Kasumi F; Fukami A; Nakajima T; Nishi M; Kajitani T; Takahashi S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2310-5. PubMed ID: 3475042
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen.
Fujino N; Haga Y; Sakamoto K; Egami H; Kimura M; Nishimura R; Akagi M
Jpn J Clin Oncol; 1986 Dec; 16(4):335-46. PubMed ID: 3467106
[TBL] [Abstract][Full Text] [Related]
11. Efficient test for cancer antigens: decreased levels of cancer antigen in serum after excision of breast tumor.
Eskelinen M; Tikanoja S; Collan Y
Anticancer Res; 1989; 9(2):437-9. PubMed ID: 2751269
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
13. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
14. [Carbohydrate antigen (CA-19-9) in the blood serum of patients with benign and malignant liver diseases].
Ametov AS; Kasatkin IuN; Mit'kov VV; Gur'eva IV
Med Radiol (Mosk); 1985 Mar; 30(3):39-41. PubMed ID: 3856723
[TBL] [Abstract][Full Text] [Related]
15. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of a high molecular weight antigen detected by antibody W1 in sera from breast cancer patients.
Linsley PS; Ochs V; Laska S; Horn D; Ring DB; Frankel AE; Brown JP
Cancer Res; 1986 Oct; 46(10):5444-50. PubMed ID: 2428478
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
Crombach G; Zippel HH; Würz H
Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
[TBL] [Abstract][Full Text] [Related]
18. MCA performance in preoperative breast cancer patients.
Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of CA 15-3 radioimmunoassay].
Takemori Y; Odani H; Watanabe H; Ohta H; Satomura Y; Okai T; Sawabu N; Mai M; Hattori N; Hashimoto T
Gan To Kagaku Ryoho; 1987 Jan; 14(1):114-8. PubMed ID: 3467654
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of tumor marker CA15-3 in breast cancer].
Kikuchi K; Uematsu Y; Takada Y; Kurihara E; Suito T; Fujisaki M; Takahashi R; Tamura T
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3095-100. PubMed ID: 3479052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
